Expertise in
17
conditions

Dr. Morris D. Groves

Neurology
901 W 38th St Ste 200, 
Austin, TX 
Expertise in
17
conditions
901 W 38th St Ste 200, 
Austin, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Morris Groves is a Neurologist in Austin, Texas. Dr. Groves is highly rated in 17 conditions, according to our data. His top areas of expertise are Brain Tumor, Glioma, Glioblastoma, and Astrocytoma.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO

Locations

901 W 38th St Ste 200, Austin, TX 78705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative
Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative
Enrollment Status: Terminated
Publish Date: November 19, 2024
Intervention Type: Other, Radiation, Procedure, Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

43 Total Publications

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: July 21, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Michael J. Soileau
Neurology
Expertise in
17
conditions
Dr. Michael J. Soileau
Neurology

Texas Movement Disorder Specialists, PLLC

Georgetown, TX 
 (24.9 miles away)
512-693-4041
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Soileau is a Neurologist in Georgetown, Texas. Dr. Soileau has been practicing medicine for over 16 years is highly rated in 17 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Movement Disorders, Essential Tremor, Deep Brain Stimulation, and Gastrostomy. Dr. Soileau is currently accepting new patients.

Expertise in
32
conditions
Dr. Elizabeth L. Peckham
Neurology
Expertise in
32
conditions
Dr. Elizabeth L. Peckham
Neurology

Central Texas Neurology Consultants PA

16040 Park Valley Dr, 
Round Rock, TX 
 (14.5 miles away)
512-218-1222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Peckham is a Neurologist in Round Rock, Texas. Dr. Peckham is highly rated in 32 conditions, according to our data. Her top areas of expertise are Movement Disorders, Parkinson's Disease, Essential Tremor, Dopa-Responsive Dystonia, and Deep Brain Stimulation. Dr. Peckham is currently accepting new patients.

Expertise in
10
conditions
Dr. Sami M. Aboumatar
Neurology
Expertise in
10
conditions
Dr. Sami M. Aboumatar
Neurology
2200 Park Bend Dr, Bldg 2 203, 
Austin, TX 
 (7.6 miles away)
512-339-8831
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Sami Aboumatar is a Neurologist in Austin, Texas. Dr. Aboumatar is highly rated in 10 conditions, according to our data. His top areas of expertise are Seizures, Memory Loss, Status Epilepticus, and Generalized Tonic-Clonic Seizure. Dr. Aboumatar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Groves's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile